Reproducibility of tumor perfusion measurements using15O-labeled water and PET

Journal of Nuclear Medicine

Volumn 49, Issue 11, 2008, Pages 1763-1768

  De Langen, Adrianus J ^a   Lubberink, Mark ^a   Boellaard, Ronald ^a   Spreeuwenberg, Marieke D ^a   Smit, Egbert F ^a   Hoekstra, Otto S ^a   Lammertsma, Adriaan A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Blood flow; Non small cell lung cancer; Perfusion; Positron emission tomography

Indexed keywords

FLUORODEOXYTHYMIDINE F 18; TRACER; UNCLASSIFIED DRUG; WATER O 15;

ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; HUMAN; IMAGE ANALYSIS; LUNG NON SMALL CELL CANCER; LUNG PERFUSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; TUMOR BLOOD FLOW;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; OXYGEN RADIOISOTOPES; PERFUSION; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; WATER;

EID: 57349139105     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.053454     Document Type: Article

References (33)

1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
2. Anderson H, Yap JT, Wells P, et al. Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br J Cancer. 2003;89:262-267.
3. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol. 2003;21:2823-2830.
4. Herbst RS, Mullani NA, Davis DW, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol. 2002;20:3804-3814.
5. 15O positron emission tomography. J Cereb Blood Flow Metab. 2002;22:1149-1156.
6. 15O PET studies. J Cereb Blood Flow Metab. 2006;26:48-57.
7. 15O-labeled water and PET. J Nucl Med. 1999;40:1848-1856.
8. 2 positron emission tomography measurements of blood flow in patients with intra-abdominal cancers. Clin Cancer Res. 2003;9:6350-6356.
9. Wilson CB, Lammertsma AA, McKenzie CG, Sikora K, Jones T. Measurements of blood flow and exchanging water space in breast tumours using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res. 1992;52:1592-1597.
10. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989;49:6449-6465.
11. Boellaard R, van Lingen A, van Balen SC, Lammertsma AA. Optimization of attenuation correction for positron emission tomography studies of thorax and pelvis using count-based transmission scans. Phys Med Biol. 2004;49:N31-N38.
12. Erdi YE, Mawlawi O, Larson SM, et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer. 1997;80:2505-2509.
13. 15O-water and positron emission tomography. Mol Imaging Biol. 2005;7:273-285.
14. Hoekstra CJ, Hoekstra OS, Lammertsma AA. On the use of image-derived input functions in oncological fluorine-18 fluorodeoxyglucose positron emission tomography studies. Eur J Nucl Med. 1999;26:1489-1492.
15. 18F-FDG PET scans. J Nucl Med. 2001;42:1622-1629.
16. 15O and positron emission tomography. Clin Cancer Res. 2002;8:2109-2115.
17. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;AC-19:716-723.
18. Schwarz G. Estimating the dimension of a model. Ann Statist. 1978;6:461-464.
19. 18F-FDG PET. J Nucl Med. 2002;43:1304-1309.
20. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
21. 15O]water and positron emission tomography. Nucl Med Commun. 2003;24:497-501.
22. 15O] water and positron emission tomography. Nucl Med Commun. 2001;22:755-757.
23. Blomqvist G, Lammertsma AA, Mazoyer B, Wienhard K. Effect of tissue heterogeneity on quantification in positron emission tomography. Eur J Nucl Med. 1995;22:652-663.
24. Ziegler SI, Haberkorn U, Byrne H, et al. Measurement of liver blood flow using oxygen-15 labelled water and dynamic positron emission tomography: limitations of model description. Eur J Nucl Med. 1996;23:169-177.
25. Lammertsma AA, Cunningham VJ, Deiber MP, et al. Combination of dynamic and integral methods for generating reproducible functional CBF images. J Cereb Blood Flow Metab. 1990;10:675-686.
26. Rajasekharan S, Boellaard R, Lubberink M, Lammertsma AA, Jones T. Measurement of abdominal tumour blood flow: independent assessment of delay and dispersion of the arterial input function. Paper presented at: IEEE Medical Imaging Conference, Rome, Italy, October 16-22, 2004.
27. Inaba T. Quantitative measurements of prostatic blood flow and blood volume by positron emission tomography. J Urol. 1992;148:1457-1460.
28. 15O-water for monitoring androgen independent prostate cancer. Mol Imaging Biol. 2003;5:86-93.
29. 18F]fluoroerythronitroimidazole PET. J Nucl Med. 2001;42:1643-1652.
30. Logan TF, Jadali F, Egorin MJ, et al. Decreased tumour blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial. Cancer Chemother Pharmacol. 2002;50:433-444.
31. Schiller JH, Harrington D, Belani CP, et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
32. Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg. 1978;76:832-839.
33. Kety SS. The theory and applications of the exchange of inert gas at the lungs and tissues. Pharmacol Rev. 1951;3:1-41.